SCHEDULE: Slate Path Capital Discloses 7.5% Stake in Tvardi
Beneficial Ownership Report
Slate Path Capital LP and David Greenspan have disclosed a 7.5% passive beneficial ownership stake in Tvardi Therapeutics, Inc., holding 704,118 shares of common stock.
Summary
- Slate Path Capital LP and David Greenspan reported beneficial ownership of 704,118 shares of Tvardi Therapeutics, Inc. common stock.
- This represents 7.5% of the company's outstanding common stock.
- The ownership is shared for both voting and dispositive power.
- The filing is a Schedule 13G, indicating a passive investment, not for the purpose of changing or influencing control of the issuer.
- The percentage is calculated based on 9,360,904 shares outstanding as of May 8, 2025, as reported in the company's Quarterly Report on Form 10-Q.
Sentiment
Score: 5
Explanation: The filing is a standard Schedule 13G disclosure of passive beneficial ownership, providing no direct positive or negative information about the company's operational or financial performance.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant passive stake by an institutional investor like Slate Path Capital LP may be viewed positively by existing shareholders, signaling investor confidence in Tvardi Therapeutics, Inc.
- Management: Awareness of a significant passive institutional investor on the shareholder register.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2020-07-31 | Date David Greenspan granted Power of Attorney to Jim Feeney for SEC filings. |
| 2025-05-08 | Date as of which 9,360,904 shares of Common Stock were reported outstanding in the Company's Form 10-Q. |
| 2025-05-13 | Date Tvardi Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025. |
| 2025-06-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-08-14 | Date the Schedule 13G statement was signed and filed by Reporting Persons. |
Recommendation
holdThis filing is a Schedule 13G, indicating a passive beneficial ownership stake by Slate Path Capital LP and David Greenspan. It does not provide operational or financial performance data for Tvardi Therapeutics, Inc., nor does it suggest any intent to influence control. While the presence of an institutional investor can be a positive signal, this filing alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. Investors should consider this ownership alongside the company's financial reports, strategic developments, and market conditions.
Keywords
Tvardi Therapeutics, Slate Path Capital, David Greenspan, Beneficial Ownership, Schedule 13G, Common Stock, Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.